Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $9.50.
A number of research firms have weighed in on PRQR. Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective for the company. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a report on Monday, March 10th. Chardan Capital reissued a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th.
Get Our Latest Research Report on PRQR
ProQR Therapeutics Stock Performance
PRQR stock remained flat at $1.14 during trading on Wednesday. The company had a trading volume of 464,845 shares, compared to its average volume of 583,556. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The firm has a market capitalization of $119.94 million, a P/E ratio of -3.56 and a beta of 0.25. The stock's 50-day moving average is $1.76 and its 200-day moving average is $2.52.
Institutional Investors Weigh In On ProQR Therapeutics
A number of hedge funds have recently added to or reduced their stakes in PRQR. Alpine Global Management LLC purchased a new position in ProQR Therapeutics in the fourth quarter valued at $39,000. Woodline Partners LP acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at $9,426,000. Velan Capital Investment Management LP purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth $107,000. Squarepoint Ops LLC increased its holdings in ProQR Therapeutics by 16.3% in the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock valued at $220,000 after buying an additional 11,623 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in ProQR Therapeutics by 512.8% in the fourth quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company's stock valued at $1,015,000 after buying an additional 320,614 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.
About ProQR Therapeutics
(
Get Free ReportProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Read More
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
